Skip to content

STAR and Deferred Stenting Study

Outcomes and Safety in Patients Treated With STAR and Deferred Stenting After Unsuccessful CTO PCI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05089864
Acronym
STAR
Enrollment
150
Registered
2021-10-22
Start date
2021-11-23
Completion date
2025-08-07
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Occlusion, Coronary Restenosis, Coronary Stenosis

Keywords

chronic total occlusion, sub-intimal plaque modification

Brief summary

STAR is a minimal-risk pragmatic clinical trial of patients admitted for a CTO-PCI procedure. The overall objective of the STAR Study is to address the current gaps in knowledge regarding use of STAR during CTO-PCI, as a prospective, multi-center study of 150 participants with randomization of timing of staged PCI. Five sites will be selected to participate in STAR from a national network of highly experienced CTO-PCI centers across the United States.

Detailed description

To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting.

Interventions

OTHERStent Placement Timing - Early

Stent placement 5-7 weeks after STAR procedure

OTHERStent Placement Timing - Late

Stent placement 12-14 weeks after STAR procedure

Sponsors

Asahi-Intecc
CollaboratorUNKNOWN
Saint Luke's Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject is scheduled for a PCI procedure for at least one chronic total occlusion with TIMI antegrade flow of zero. 2. Subject is ≥ 18 years of age at the time of consent 3. The operator attempted STAR technique defined as knuckle guidewire across or into the CTO segment during the CTO PCI and is planned for a staged procedure. 4. English speaking due to follow up.

Exclusion criteria

1. The CTO segment is in a graft. 2. Female subjects with a positive quantitative or qualitative pregnancy test, in accordance with hospital policy. 3. Unable to participate in telephone follow-up 1. Too hard of hearing to do follow-up by telephone or deaf. 2. Incarcerated prisoner. 3. History of dementia. 4. Subjects without a way for contact by telephone for follow-up. 4. Previously enrolled in STAR. 5. Patient not a candidate for baseline and final angiography (CKD with eGFR\<30). 6. The knuckled guidewire did not cross into the CTO segment during STAR attempt. 7. A stent was placed into the STAR segment during the Index Procedure. 8. Refused participation in the study. 9. Patient enrolled in another study.

Design outcomes

Primary

MeasureTime frameDescription
Staged Procedure Success14 weekssuccess of the staged stenting procedure will be core lab adjudicated and defined as TIMI 3 flow, no major side branch loss, and residual stenosis \<30%

Secondary

MeasureTime frameDescription
Vessel patency at time of staged stenting procedure14 weeksnumber of distal branches, and the antegrade TIMI flow through the vessel, assessed by core-lab analysis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026